Head and Neck Squamous Cell Carcinomas (HNSCC) Market Research Report 2023: Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecasts, 2021-2031

DUBLIN, April 7, 2023 /PRNewswire/ -- The "Head and Neck Squamous Cell Carcinomas (HNSCC) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to  ResearchAndMarkets.com's offering.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for Head and Neck Squamous Cell Carcinomas (HNSCC).

In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional 7 geographical markets (7M), totaling 15 major markets (15MM). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the publisher's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

The report also analyzes the clinical and commercial landscapes of GBM, with pricing assumptions based on currently marketed products by class of cell & gene therapies, accompanied by a transparent forecast methodology. Additionally, the report evaluates indication-specific unmet needs and competitive assessment, and identifies key future players in the cell therapy market.

Cell and gene therapy (CGT) is not an established therapy area in HNSCC, but there is an active clinical pipeline. Gene therapies dominate the HNSCC CGT pipeline with 10 agents in Phase II and 13 agents in Phase I. Autologous T-cell receptors (TCRs) follow close behind with 3 agents in Phase II and 7 agents in Phase I of development. However, CGTs only constitute a modest proportion of the overall HNSCC pipeline, reflecting the unproven efficacy of these modalities in this cancer type.

Cell and gene therapies are expected to capture a combined total of 8% of the HNSCC market by the end of the forecast period in 2031, reaching $262 million in 8MM sales (US, France, Germany, Italy, Spain, UK, Japan, and China).

Sales forecasts for the 7M (Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada) assessed in this analysis show the overall HNSCC market (cell therapies and established/traditional therapies) is expected to reach $163 million by 2031.

CGT agents show promise for partially meeting unmet needs in HNSCC and can provide the most value by producing more therapeutic options for patients with locally advanced HNSCC. CGTs are not expected to address the unmet need of identifying new druggable targets, with the top 5 targets in the HNSCC already being well-established targets.

Key Questions Answered

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?

A selection of companies mentioned in this report includes

• Replimune Ltd
• SQZ Biotechnologies
• Iovance Biotherapeutics Inc

Key Highlights

• Forecast includes 8 countries
• Forecast covers 2021-2031
• Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics

Reasons to Buy

• Obtain cell & gene therapy sales forecasts across multiple regions
• Gain insight into promising early stage approaches

Key Topics Covered:

1. Preface
1.1. Contents
1.2. Report Scope

2. Executive Summary

3. Disease Overview
3.1. HNSCC Etiology & Treatment Algorithm 1
3.2. Treatment Algorithm 2

4. Marketed & Pipeline Drugs Overview
4.1. Marketed Drugs Overview
4.2. Pipeline Analysis
4.3. Target Analysis and Clinical Benchmarks

5. Market Outlook
5.1. 10-Year Market Analysis with Drivers and Barriers
5.2. 10-Year Market Outlook - 15 Markets

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment
8.1. Competitive Analysis by Class of Therapy

9. Future Players
9.1. Future Players Based on Pipeline Strength

10. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9s4525

Source: GlobalData

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets